Neil Blumberg: Clinical Harm Associated With Infusion of ABO Incompatible Antibody and Antigen
Neil Blumberg, Transfusion Medicine Specialist and Platelet Researcher (Former Professor and Director, URMC), shared on LinkedIn:
“Some ideas become dogma without any strong data to support them. Examples include the equivalent safety of universal donor group O red cells and group AB plasma to ABO identical transfusions. Data have now accumulated to show that these assumptions are largely incorrect.
Our group reviewed the data demonstrating that infusion of modest amounts of ABO incompatible cellular and soluble antigen, and ABO incompatible plasma are associated with clinical harm, including increased mortality.
Tong N, Masel D, Nguyen PL, Asante A, Refaai M, Heal JM, Blumberg N.
The case against infusing ABO incompatible antibody and antigen from all blood components.
Transfus Apher Sci. 2026 Jan 31;65(2):104402. doi: 10.1016/j.transci.2026.104402. Epub ahead of print. PMID: 41633302.
Abstract
The transfusion of ABO compatible but not ABO identical red blood cells and plasma and the transfusion of platelets and cryoprecipitate without concern for ABO in any manner, are practices that have been accepted as safe for patients.
While these practices make managing blood component inventories easier by reducing component outdating, they do lead to the development of immune complexes, donor antibody induced hemolysis, and potentially endothelial cell and platelet injury.
A growing body of evidence has shown that these practices are associated, likely causally, with negative consequences for patients including increased mortality.
The adoption of a policy of providing only ABO identical blood components when practical, and avoiding infusion of ABO incompatible antibody, cellular and soluble antigen should thus become the optimal standard of care for patients.
For those without access to the full article, request a .pdf from [email protected].”
Find more posts featuring Neil Blumberg on Hemostasis Today.
-
Sep 24, 2026, 16:02Leonardo Roever: Understanding Peripheral Artery Disease in the Modern Era
-
Sep 24, 2026, 15:49Sthanu Subramanian: When HbA1c Does Not Reflect True Glycemia
-
Sep 24, 2026, 15:09Caroline Voltz-Girolt: Accelerating the Development of Innovative Therapies for Rare Blood Disorders
-
Sep 24, 2026, 15:00Gambo Ramatu: Anemia as a Preventable Pregnancy Challenge
-
Sep 24, 2026, 14:56Holly John: Sickle Cell Disease Beyond Pain and Clinical Outcomes
-
Sep 24, 2026, 14:45Bruce Holland: Ex Vivo Assessment of ActiGraft Clot Formation Under Anticoagulation
-
Sep 24, 2026, 14:33Mohamed El Belghiti Alaoui: Thrombin as a Therapeutic Target in Coagulation
-
Sep 24, 2026, 14:22Integrating Thrombosis Risk Into Menopause Care – World Thrombosis Day
-
Sep 24, 2026, 13:41Mahmoud Samir Bayomi: Raise ITP Awareness and Improve Patient Care